prostate adenocarcinoma (Cancer)
Information
- Disease name
- prostate adenocarcinoma
- Disease ID
- DOID:2526
- Description
- "A prostate carcinoma that derives_from epithelial cells of glandular origin." [url:http\://cancergenome.nih.gov/cancersselected/prostatecancer, url:http\://en.wikipedia.org/wiki/Adenocarcinoma, url:http\://en.wikipedia.org/wiki/Prostate_cancer]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04190446 | Active, not recruiting | Phase 2 | Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment | January 6, 2020 | December 31, 2024 |
| NCT03246347 | Active, not recruiting | Phase 2 | A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer | August 23, 2017 | March 2028 |
| NCT05496959 | Active, not recruiting | Phase 2 | 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study | September 2, 2022 | September 1, 2025 |
| NCT03274687 | Active, not recruiting | Phase 3 | Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer | July 28, 2017 | November 2026 |
| NCT04019327 | Active, not recruiting | Phase 1/Phase 2 | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | July 11, 2019 | July 2027 |
| NCT04743934 | Active, not recruiting | Phase 2 | Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer | July 2, 2021 | March 2026 |
| NCT03361735 | Active, not recruiting | Phase 2 | Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | August 29, 2018 | April 9, 2025 |
| NCT02031328 | Active, not recruiting | Phase 1/Phase 2 | Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer | January 2014 | September 12, 2024 |
| NCT05055843 | Active, not recruiting | N/A | Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer | August 10, 2021 | January 31, 2025 |
| NCT05003752 | Active, not recruiting | Phase 1/Phase 2 | Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer | August 1, 2021 | August 1, 2026 |
| NCT03412396 | Active, not recruiting | Phase 2 | Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy | March 22, 2018 | July 30, 2024 |
| NCT04045717 | Active, not recruiting | Phase 2 | Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0 | April 10, 2020 | February 16, 2032 |
| NCT04624256 | Active, not recruiting | N/A | Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial | November 10, 2020 | December 31, 2028 |
| NCT04446117 | Active, not recruiting | Phase 3 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC | June 30, 2020 | August 31, 2024 |
| NCT01786265 | Active, not recruiting | Phase 2 | Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | February 5, 2013 | February 1, 2025 |
| NCT05779943 | Active, not recruiting | Phase 2 | Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer | April 27, 2023 | July 1, 2028 |
| NCT03963739 | Active, not recruiting | Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer | July 19, 2019 | December 31, 2024 | |
| NCT04126070 | Active, not recruiting | Phase 2 | Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors | May 11, 2020 | June 30, 2025 |
| NCT04985565 | Active, not recruiting | N/A | Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer | August 27, 2021 | October 20, 2025 |
| NCT04030338 | Active, not recruiting | Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer | July 19, 2019 | July 2025 | |
| NCT02254746 | Active, not recruiting | N/A | A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer | September 2014 | March 2024 |
| NCT04384770 | Active, not recruiting | CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study | May 12, 2020 | April 1, 2027 | |
| NCT03570827 | Active, not recruiting | Phase 2 | Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy | May 8, 2018 | May 8, 2025 |
| NCT03581500 | Active, not recruiting | Phase 2 | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer | February 6, 2019 | July 31, 2024 |
| NCT05276492 | Active, not recruiting | Phase 1 | Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. | January 24, 2023 | November 1, 2025 |
| NCT03654638 | Active, not recruiting | Phase 2 | Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer | August 15, 2018 | March 1, 2025 |
| NCT01352429 | Active, not recruiting | Mild Hypofractionation With Proton Therapy or Intensity Modulated Radiation Therapy (IMRT) for Intermediate-Risk Prostate Cancer | August 2009 | December 2025 | |
| NCT04336943 | Active, not recruiting | Phase 2 | Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load | April 13, 2021 | June 6, 2025 |
| NCT01411345 | Active, not recruiting | N/A | MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial | July 12, 2012 | February 13, 2028 |
| NCT03762759 | Active, not recruiting | Phase 2 | Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes | May 10, 2019 | December 31, 2025 |
| NCT01953640 | Active, not recruiting | Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy | May 28, 2013 | June 30, 2024 | |
| NCT03796767 | Active, not recruiting | Phase 2 | Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer | September 9, 2019 | June 30, 2026 |
| NCT03805594 | Active, not recruiting | Phase 1 | 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | May 10, 2019 | April 30, 2025 |
| NCT04288687 | Active, not recruiting | Phase 2 | A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects | October 19, 2020 | June 2024 |
| NCT03821792 | Active, not recruiting | Phase 2 | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | July 22, 2019 | October 1, 2024 |
| NCT04286386 | Active, not recruiting | Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam | December 19, 2019 | April 30, 2026 | |
| NCT02346253 | Active, not recruiting | N/A | High-Dose Brachytherapy in Treating Patients With Prostate Cancer | January 13, 2015 | December 2026 |
| NCT03204123 | Active, not recruiting | Phase 2 | PSMA PET Imaging of Recurrent Prostate Cancer | June 26, 2017 | June 2024 |
| NCT03860961 | Active, not recruiting | N/A | Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy | August 2, 2019 | November 30, 2029 |
| NCT04377152 | Approved for marketing | Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer | |||
| NCT02673151 | Completed | Phase 2/Phase 3 | 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment | May 20, 2017 | April 27, 2019 |
| NCT04978675 | Completed | Phase 1 | An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer | August 4, 2021 | June 4, 2024 |
| NCT02940262 | Completed | Phase 3 | Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy | September 15, 2016 | June 18, 2021 |
| NCT02981797 | Completed | Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223 | July 22, 2015 | November 5, 2020 | |
| NCT03034070 | Completed | N/A | Whole-Body 3D T1-weighted MR Imaging Anatomical Sequences: GE mDixon vs FSE (View) Approaches in Prostate Cancer. | December 2016 | March 1, 2019 |
| NCT04976257 | Completed | Early Phase 1 | Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion | October 13, 2021 | March 22, 2023 |
| NCT03177460 | Completed | Phase 1 | Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer | June 7, 2017 | January 30, 2024 |
| NCT03204812 | Completed | Phase 2 | Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer | July 14, 2017 | April 13, 2021 |
| NCT04946214 | Completed | N/A | A Behavioral Health Intervention Using Digital Technology in Radiation Therapy for Prostate Cancer Patients | May 26, 2021 | August 4, 2022 |
| NCT03368547 | Completed | N/A | 68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery | December 12, 2016 | June 18, 2021 |
| NCT03396874 | Completed | Phase 2 | Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence | February 9, 2018 | August 9, 2022 |
| NCT03404648 | Completed | Phase 3 | Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI | November 1, 2017 | January 23, 2020 |
| NCT04638049 | Completed | N/A | Intestinal Microbiota in Prostate Cancer Patients as a Biomarker for Radiation-INduced Toxicity (IMPRINT) | August 25, 2020 | August 8, 2022 |
| NCT04428203 | Completed | Phase 1 | Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer | August 3, 2020 | August 20, 2021 |
| NCT03496844 | Completed | N/A | Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma | April 15, 2018 | April 27, 2021 |
| NCT03504995 | Completed | N/A | Efficacy and Safety Assessment of IRE of Localized Prostate Cancer. | April 19, 2018 | April 30, 2020 |
| NCT03516812 | Completed | Phase 2 | Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer | August 29, 2018 | April 12, 2024 |
| NCT04400656 | Completed | PROState Pathway Embedded Comparative Trial | September 8, 2020 | August 31, 2022 | |
| NCT03698370 | Completed | Phase 2 | Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer | December 15, 2020 | February 11, 2022 |
| NCT03739684 | Completed | Phase 3 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer | November 27, 2018 | August 29, 2019 |
| NCT03780023 | Completed | CCRO044: Quality of Life Assessments Associated With a Physician Communication Intervention for Prostate Cancer Patients | July 17, 2017 | May 4, 2020 | |
| NCT04284761 | Completed | Phase 1 | A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer | October 11, 2020 | May 3, 2023 |
| NCT03830164 | Completed | Phase 2 | Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer | November 20, 2019 | November 2, 2022 |
| NCT03279250 | Completed | Phase 2 | Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer | October 13, 2017 | May 11, 2021 |
| NCT00181597 | Completed | Phase 2 | Trilostane for Androgen-Independent Prostate Cancer | March 2004 | January 2006 |
| NCT00183924 | Completed | Phase 2 | Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. | March 2001 | December 2008 |
| NCT00379132 | Completed | Phase 1 | 131-I-TM-601 Study in Adults With Solid Tumors | August 2006 | August 2008 |
| NCT00170157 | Completed | Phase 2 | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | June 2004 | June 2013 |
| NCT00589472 | Completed | Phase 2 | Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer | November 2007 | June 2010 |
| NCT00773656 | Completed | Patients Overexposed for a Prostate Adenocarcinoma | October 2008 | May 2013 | |
| NCT00887432 | Completed | N/A | Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation | April 8, 2009 | June 8, 2020 |
| NCT01026623 | Completed | Phase 1/Phase 2 | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer | October 2009 | February 2013 |
| NCT01120236 | Completed | Phase 2 | Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | December 2010 | August 23, 2017 |
| NCT06299046 | Completed | Bleeding After Robot-assisted Radical Prostatectomy: a Respective Study | December 1, 2022 | January 1, 2023 | |
| NCT01148069 | Completed | Phase 2 | Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers | July 30, 2010 | July 4, 2018 |
| NCT06029088 | Completed | Risk-adapted Strategy Including Magnetic Resonance Imaging and Prostate-specific Antigen Density in Blood for Biopsy Decision in Patients With Lesions Suspicious for Prostate Cancer | January 12, 2023 | June 16, 2023 | |
| NCT01219790 | Completed | Phase 1 | ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma | October 2010 | November 2015 |
| NCT05803096 | Completed | Phase 4 | Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain | December 12, 2021 | September 9, 2022 |
| NCT01325311 | Completed | Phase 2 | Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer | December 2011 | July 2014 |
| NCT01347788 | Completed | Phase 1 | Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer | April 2011 | May 2013 |
| NCT01411319 | Completed | N/A | MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer | December 27, 2011 | March 2, 2020 |
| NCT01411332 | Completed | N/A | Hypofractionated Image-Guided Radiotherapy For Prostate Cancer: The HEIGHT Trial | October 31, 2011 | November 22, 2021 |
| NCT01505868 | Completed | Phase 1/Phase 2 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | July 11, 2012 | December 9, 2019 |
| NCT01519414 | Completed | Phase 2 | Tivantinib in Treating Patients With Metastatic Prostate Cancer | January 11, 2012 | August 18, 2015 |
| NCT01530269 | Completed | Phase 2 | C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma | April 2012 | January 2019 |
| NCT01661166 | Completed | Phase 4 | A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy | January 2012 | April 15, 2013 |
| NCT01709253 | Completed | N/A | Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma | March 2007 | December 2015 |
| NCT01731912 | Completed | N/A | Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer | May 2013 | September 2016 |
| NCT05735223 | Completed | N/A | A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence | September 30, 2021 | January 15, 2023 |
| NCT01787331 | Completed | Phase 2 | Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer | October 29, 2013 | September 30, 2018 |
| NCT05589558 | Completed | N/A | Prospective Comparison of the Four Biopsy Methods for Prostate Cancer Detection | October 1, 2020 | February 25, 2022 |
| NCT01856855 | Completed | N/A | Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203) | February 2013 | December 2022 |
| NCT01898065 | Completed | Phase 2 | Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer | June 2012 | February 2015 |
| NCT02175212 | Completed | Phase 3 | Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer | November 2005 | September 24, 2020 |
| NCT02206334 | Completed | Phase 1 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer | August 2014 | May 20, 2022 |
| NCT02228265 | Completed | Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide | March 12, 2013 | February 27, 2020 | |
| NCT02268175 | Completed | Phase 2 | Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | October 2014 | December 2021 |
| NCT02285101 | Completed | Phase 1 | Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors | November 2014 | February 2019 |
| NCT02339948 | Completed | N/A | Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma | June 2006 | October 2019 |
| NCT05197257 | Completed | Phase 3 | 68Ga-PSMA-11 PET in Patients With Prostate Cancer | September 29, 2021 | April 14, 2022 |
| NCT02499835 | Completed | Phase 1/Phase 2 | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer | July 1, 2015 | July 27, 2023 |
| NCT02603965 | Completed | Phase 1 | Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery | August 2013 | September 2014 |
| NCT02624518 | Completed | Phase 2/Phase 3 | 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer | November 16, 2015 | November 2022 |
| NCT04050215 | Completed | Phase 2 | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer | April 2, 2018 | September 27, 2021 |
| NCT06347809 | Enrolling by invitation | DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine | November 7, 2018 | February 1, 2029 | |
| NCT03503643 | Enrolling by invitation | Hemi-Gland Cryoablation for Prostate Cancer at UCLA | September 14, 2017 | December 31, 2025 | |
| NCT03501940 | No longer available | F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer | |||
| NCT05415228 | No longer available | Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer | |||
| NCT06446648 | Not yet recruiting | Early Phase 1 | Relationship bw Image-deriv Features of Intraoperative ICG Visualiz of NVBs During RARP & Functional Outcome | June 15, 2024 | June 2028 |
| NCT05610852 | Not yet recruiting | N/A | Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound | June 1, 2024 | July 1, 2028 |
| NCT05665738 | Not yet recruiting | N/A | Two-fraction HDR Monotherapy for Localized Prostate Cancer | April 30, 2024 | October 31, 2025 |
| NCT05919329 | Not yet recruiting | Phase 4 | Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy | May 1, 2024 | September 1, 2029 |
| NCT06022822 | Not yet recruiting | Phase 2 | Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial | July 8, 2024 | November 1, 2026 |
| NCT06257693 | Not yet recruiting | Phase 1 | Enzalutamide Implants (Enolen) in Patients With Prostate Cancer | February 2024 | August 2025 |
| NCT06312670 | Not yet recruiting | Phase 2 | Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer | August 1, 2024 | March 1, 2026 |
| NCT06330805 | Not yet recruiting | Phase 2 | Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer | April 1, 2024 | December 31, 2027 |
| NCT06387238 | Not yet recruiting | N/A | Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer | May 1, 2024 | June 30, 2026 |
| NCT04513717 | Recruiting | Phase 3 | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial | December 15, 2020 | December 31, 2033 |
| NCT04704505 | Recruiting | Phase 2 | Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) | April 28, 2022 | February 2027 |
| NCT03285815 | Recruiting | N/A | Prostate Cancer - Localized Adenocarcinoma Proton Therapy | May 2016 | December 2025 |
| NCT04777071 | Recruiting | Phase 2 | An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer | May 17, 2021 | March 31, 2028 |
| NCT04802876 | Recruiting | Phase 2 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors | April 12, 2021 | March 31, 2027 |
| NCT04870515 | Recruiting | N/A | Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study | November 4, 2021 | June 30, 2025 |
| NCT04915508 | Recruiting | Phase 2 | Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy | June 23, 2021 | August 1, 2027 |
| NCT04943536 | Recruiting | Phase 1 | Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer | October 1, 2021 | December 31, 2024 |
| NCT04945642 | Recruiting | N/A | High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma | August 20, 2021 | July 1, 2026 |
| NCT04983862 | Recruiting | Phase 1 | Fluorescent Imaging of Nerves With Illuminare-1 During Surgery | October 4, 2021 | October 4, 2025 |
| NCT05001477 | Recruiting | Customized TULSA-PRO Ablation Registry | October 27, 2021 | October 2061 | |
| NCT02600156 | Recruiting | N/A | Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors | September 1, 2015 | December 2025 |
| NCT05022914 | Recruiting | PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE | January 19, 2021 | January 19, 2027 | |
| NCT05027477 | Recruiting | N/A | A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer | November 1, 2021 | December 9, 2034 |
| NCT05050084 | Recruiting | Phase 3 | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | November 3, 2021 | April 30, 2037 |
| NCT05053152 | Recruiting | Phase 2 | Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer | December 8, 2021 | October 10, 2029 |
| NCT05109208 | Recruiting | N/A | The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction | October 2, 2023 | October 2025 |
| NCT01985828 | Recruiting | N/A | CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer | November 19, 2013 | December 2026 |
| NCT05600400 | Recruiting | N/A | Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer | March 1, 2024 | June 2029 |
| NCT05616650 | Recruiting | Phase 2 | Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor | October 19, 2023 | December 1, 2028 |
| NCT05679388 | Recruiting | Phase 1 | A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients | February 13, 2023 | April 1, 2025 |
| NCT05683964 | Recruiting | Early Phase 1 | Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | January 19, 2023 | February 1, 2025 |
| NCT05709496 | Recruiting | N/A | Dose De-escalation in Prostate Radiotherapy Using the MRL | March 1, 2023 | March 1, 2027 |
| NCT05710380 | Recruiting | N/A | MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy | April 26, 2023 | May 1, 2026 |
| NCT05726292 | Recruiting | Phase 2 | A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer | October 9, 2023 | April 1, 2029 |
| NCT05751434 | Recruiting | Phase 2 | A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer | February 10, 2023 | February 10, 2027 |
| NCT05806515 | Recruiting | Phase 2 | Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | March 1, 2024 | June 2028 |
| NCT05832086 | Recruiting | Phase 2 | Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes | September 13, 2023 | March 30, 2029 |
| NCT05852041 | Recruiting | Early Phase 1 | rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance | August 7, 2023 | June 7, 2035 |
| NCT05902637 | Recruiting | N/A | The Efficacy Of Mapping For Cognitive Prostate Biopsy | March 1, 2023 | September 1, 2023 |
| NCT06392295 | Recruiting | Phase 2 | PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer | August 1, 2024 | August 1, 2029 |
| NCT05919524 | Recruiting | N/A | SBRT With Focal Dose Escalation on DIL in Localized Prostate Cancer | August 1, 2023 | June 30, 2025 |
| NCT05931419 | Recruiting | High-Risk prostatE Cancer radiatiOn Versus surgERy | February 16, 2023 | June 30, 2030 | |
| NCT05960578 | Recruiting | Phase 2 | Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study | May 6, 2024 | December 31, 2027 |
| NCT05998278 | Recruiting | N/A | Personalized Optimization of Systematic Prostate Biopsy | August 23, 2023 | December 1, 2025 |
| NCT06044857 | Recruiting | Phase 1 | PSMA PET Response Guided SabR in High Risk Pca | March 7, 2024 | November 2026 |
| NCT06067269 | Recruiting | Phase 2 | Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial | March 28, 2024 | December 1, 2027 |
| NCT06105918 | Recruiting | Phase 1 | Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer | November 29, 2023 | April 1, 2029 |
| NCT06141993 | Recruiting | ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials | May 13, 2024 | October 2026 | |
| NCT06184464 | Recruiting | Prostatic Size Reduction Following of Leuprorelin Acetate | February 2, 2024 | December 15, 2024 | |
| NCT06200259 | Recruiting | N/A | Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement | January 8, 2024 | January 2, 2040 |
| NCT06235099 | Recruiting | Phase 3 | Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer | April 1, 2024 | July 2025 |
| NCT06235151 | Recruiting | Phase 3 | Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer | April 1, 2024 | July 2025 |
| NCT06238713 | Recruiting | N/A | Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP) | February 2024 | December 2025 |
| NCT06369610 | Recruiting | Phase 2 | Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer | April 22, 2024 | April 22, 2027 |
| NCT06292897 | Recruiting | Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression | March 20, 2023 | January 15, 2027 | |
| NCT04049747 | Recruiting | N/A | Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer | December 11, 2019 | May 2027 |
| NCT03933670 | Recruiting | Phase 2 | Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance | July 18, 2018 | October 31, 2025 |
| NCT04134260 | Recruiting | Phase 3 | Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer | March 5, 2020 | November 1, 2026 |
| NCT04146077 | Recruiting | Active Surveillance for Low Risk Prostate Cancer | October 1, 2019 | October 2026 | |
| NCT04175431 | Recruiting | Phase 2 | Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study | September 30, 2020 | July 1, 2029 |
| NCT03880422 | Recruiting | N/A | Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors | May 2, 2019 | May 2, 2029 |
| NCT03822494 | Recruiting | N/A | CyberKnife Dose Escalation Prostate Cancer Trial | July 12, 2018 | July 12, 2028 |
| NCT03821246 | Recruiting | Phase 2 | Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | October 30, 2019 | February 28, 2025 |
| NCT04300855 | Recruiting | Phase 2 | Clinical Trial of Green Tea Catechins in Men on Active Surveillance | August 21, 2020 | June 30, 2025 |
| NCT03561961 | Recruiting | N/A | Prostate Radiotherapy Comparing Moderate and Extreme Hypo-fractionation (PRIME Trial) | May 24, 2018 | March 2035 |
| NCT04423211 | Recruiting | Phase 3 | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | October 8, 2020 | December 31, 2032 |
| NCT04465500 | Recruiting | Phase 2 | EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer | July 30, 2020 | January 1, 2029 |
| NCT04486755 | Recruiting | Phase 1 | Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) | November 19, 2020 | August 2027 |
| NCT04053842 | Recruiting | Phase 2 | Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy | February 4, 2021 | August 31, 2024 |
| NCT04519879 | Recruiting | Phase 2 | White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA | May 10, 2021 | April 30, 2024 |
| NCT04530552 | Recruiting | Phase 2 | Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland | July 23, 2021 | January 31, 2027 |
| NCT04543903 | Recruiting | N/A | Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer | May 16, 2022 | May 1, 2025 |
| NCT05676463 | Suspended | Phase 2 | MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer | November 16, 2022 | December 31, 2027 |
| NCT03899987 | Suspended | Phase 2 | Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery | November 29, 2019 | May 29, 2024 |
| NCT05064111 | Suspended | Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy | September 1, 2024 | September 1, 2027 | |
| NCT04037254 | Suspended | Phase 2 | Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer | June 3, 2019 | December 31, 2028 |
| NCT04252625 | Suspended | Phase 2 | Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis | June 13, 2022 | June 2026 |
| NCT01145508 | Terminated | Phase 2 | Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | August 2010 | October 2015 |
| NCT00937768 | Terminated | Phase 2 | Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | July 2009 | July 2012 |
| NCT04085991 | Terminated | Phase 2 | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer | July 31, 2020 | January 15, 2023 |
| NCT00536991 | Terminated | Phase 1/Phase 2 | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer | October 2006 | October 2016 |
| NCT02564549 | Terminated | N/A | MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca | October 5, 2015 | October 13, 2017 |
| NCT02721979 | Terminated | Phase 2 | Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance | November 2, 2017 | November 30, 2021 |
| NCT03718338 | Terminated | Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma | October 8, 2019 | March 12, 2020 | |
| NCT03649841 | Terminated | Phase 2 | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer | June 29, 2020 | February 1, 2023 |
| NCT01737151 | Terminated | N/A | Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer | March 8, 2013 | November 9, 2017 |
| NCT02853097 | Terminated | Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients | June 14, 2016 | September 27, 2020 | |
| NCT03553212 | Terminated | N/A | Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy | October 30, 2018 | May 26, 2023 |
| NCT02491411 | Terminated | N/A | Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel | September 2015 | March 2018 |
| NCT04951492 | Terminated | Phase 2 | Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma | November 9, 2022 | October 15, 2023 |
| NCT05744115 | Terminated | Phase 3 | Ga-68-PSMA-11 in Men With Prostate Cancer | July 27, 2021 | April 14, 2022 |
| NCT02454517 | Terminated | N/A | Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer | May 19, 2016 | September 30, 2021 |
| NCT02168062 | Terminated | Phase 2 | Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer | June 16, 2014 | May 22, 2018 |
| NCT01163084 | Terminated | Phase 1/Phase 2 | Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer | July 9, 2010 | June 1, 2012 |
| NCT01253642 | Terminated | Phase 2 | Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel | July 12, 2010 | September 15, 2017 |
| NCT04221828 | Terminated | Phase 2 | Trial of NanoPac Focal Therapy for Prostate Cancer | October 20, 2020 | February 8, 2021 |
| NCT03829930 | Terminated | Phase 1 | Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | May 1, 2019 | September 1, 2020 |
| NCT03999515 | Terminated | Phase 2 | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | April 27, 2020 | June 6, 2021 |
| NCT05607342 | Terminated | Early Phase 1 | Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate | January 3, 2023 | November 6, 2023 |
| NCT03996993 | Unknown status | Defining Recurrent Disease With Axumin™ | July 1, 2019 | December 30, 2020 | |
| NCT04031378 | Unknown status | Phase 2 | Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer | September 1, 2019 | November 1, 2022 |
| NCT04192890 | Unknown status | N/A | Efficacy and Safety Assessment of IRE of Localized Prostate Cancer | January 27, 2020 | December 1, 2021 |
| NCT01478412 | Unknown status | An Evaluation of Polymer Based Fiducials for Use in Imaging Patients Receiving Treatment for Prostate Cancer | December 2011 | ||
| NCT04391556 | Unknown status | Phase 2 | Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma | September 14, 2020 | March 14, 2024 |
| NCT03474835 | Unknown status | N/A | Ischemic Heart Disease in Male With Prostate Adenocarcinoma | January 15, 2018 | January 15, 2019 |
| NCT05224024 | Unknown status | N/A | Retzius-sparing Technique in Robotic-assisted Radical Prostatectomy | February 15, 2022 | December 31, 2022 |
| NCT05599737 | Unknown status | N/A | Stereotactic Prostate Radiotherapy With Dose Escalation Focused on the "Dominant Intra-prostatic Lesion" (DIPL) Delineated by Multi-parametric MRI and 68Ga-PSMA PET (Prostate-SIB-PSMA) | May 24, 2022 | May 25, 2024 |
| NCT03451812 | Unknown status | Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer | January 1, 2017 | December 31, 2019 | |
| NCT03431753 | Unknown status | N/A | Early and Accurate Detection of Prostate Cancer in General Practice | January 1, 2018 | December 31, 2021 |
| NCT04825691 | Unknown status | ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features | May 4, 2021 | May 23, 2023 | |
| NCT03255135 | Unknown status | N/A | Initial Experience in Brazilian Single Center With High Intensity Focalized Ultrasound (HIFU) Prostate Cancer Therapy: Morbidity, Oncological and Functional Outcomes. | May 31, 2018 | July 2019 |
| NCT03076372 | Unknown status | Phase 1 | A Study Evaluating MM-310 in Patients With Solid Tumors | February 22, 2017 | December 2018 |
| NCT04331717 | Withdrawn | Phase 2 | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer | November 16, 2020 | December 2023 |
| NCT03494803 | Withdrawn | Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC | June 1, 2018 | December 1, 2021 | |
| NCT03982173 | Withdrawn | Phase 2 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors | September 2020 | December 5, 2024 |
| NCT04399824 | Withdrawn | N/A | Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer | April 3, 2020 | April 3, 2020 |
| NCT04020094 | Withdrawn | Phase 2 | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer | November 20, 2019 | April 9, 2021 |
| NCT05647447 | Withdrawn | Early Phase 1 | Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate | January 3, 2023 | October 5, 2023 |
| NCT01838265 | Withdrawn | Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management | August 2012 |
- Disase is a (Disease Ontology)
- DOID:10286
- Cross Reference ID (Disease Ontology)
- NCI:C2919
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:399490008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0007112